Clinical Trial Update: A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode [Phase 2]

View source ↗

Summary

Phase 2 study evaluating SAGE-217 in participants with Bipolar I/II disorder currently experiencing a major depressive episode has completed with posted results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Major Depressive Episode

Drugs mentioned

• SAGE-217 (zuranolone)

Snippet

Sponsor: Biogen | Conditions: Bipolar Disorder I, Bipolar Disorder II | Phase 2 | Status: COMPLETED | Results posted: 2022-04-20